Navigation Links
Regeneron and Sanofi to Present Results from Four Phase 3 Alirocumab Trials in Hot Line Session at ESC Congress 2014
Date:8/24/2014

TARRYTOWN, N.Y. and PARIS, Aug. 25, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (EURONEXT: SAN and NYSE: SNY) today announced that details from four pivotal trials in the alirocumab ODYSSEY clinical program will be presented on Sunday, August 31, during a Hot Line session at ESC Congress 2014 in Barcelona, Spain, the world's largest cardiology meeting.  The data will also be highlighted in the official ESC press conference on August 31, at 09:00 CET / 03:00 ET.

Alirocumab is an investigational monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9).  Top-line results from nine ODYSSEY Phase 3 trials were announced in late July 2014.  The four trials that will be presented at ESC Congress 2014 include:

  • ODYSSEY LONG-TERM – The 2,341-patient, double-blind trial is evaluating the long-term safety and efficacy of alirocumab versus placebo in combination with maximally tolerated lipid-lowering therapy, including statins, in patients with hypercholesterolemia who are at high cardiovascular (CV) risk.
  • ODYSSEY COMBO II – The 720-patient, double-blind trial is evaluating the long-term safety and efficacy of alirocumab versus ezetimibe in combination with a maximally tolerated statin dose in high CV risk patients with hypercholesterolemia. 
  • ODYSSEY FH I and FH II – These trials involve a total of 738 patients with an inherited form of high cholesterol known as heterozygous familial hypercholesterolemia (HeFH) and compare alirocumab to placebo in combination with maximally tolerated lipid-lowering therapy, including statins.
  • The data will be presented during three ESC Congress 2014 even
    '/>"/>

    SOURCE Regeneron Pharmaceuticals, Inc.
    Copyright©2014 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. Regeneron Announces Upcoming 2014 Investor Conference Presentations
    2. Regeneron Reports Second Quarter 2014 Financial and Operating Results
    3. Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia
    4. Regeneron and Bayer to Develop New Treatment Option for Wet Age-Related Macular Degeneration
    5. Regeneron Announces Upcoming 2013 Investor Conference Presentation
    6. Sanofi and Regenerons Dupilumab Named "Clinical Advance of the Year" by Scrip Intelligence
    7. Sanofi and Regeneron Report Positive Results with Sarilumab in First Phase 3 Rheumatoid Arthritis Registration Trial
    8. Regeneron Reports Third Quarter 2013 Financial and Operating Results
    9. Regeneron Announces Appointment of Robert E. Landry as Senior Vice President, Finance and Chief Financial Officer
    10. Regenerons Eylea Now Captures One-Quarter Of Wet AMD Patient Share, Surpassing Share Of Roche/Genentechs Lucentis
    11. Quarterly Financial Results and Development Program Updates - Research Report on Regeneron, DaVita, Celldex, Isis, and VIVUS
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/23/2014)... , Sept. 23, 2014 CASI Pharmaceuticals, ... dedicated to the acquisition, development and commercialization of innovative ... the global market with a primary focus on ... Rajesh C. Shrotriya , MD, Chairman and Chief Executive ... Directors.  The appointment was made in connection with the ...
    (Date:9/23/2014)...  As physicians seek information about drugs today, ... learn about new therapies or ask questions of ... report by global sales and marketing consultants at ... a customized mix of digital media and visits ... engage with physicians. And, productive engagement with physicians ...
    (Date:9/23/2014)... 23, 2014 Avillion LLP, ... appointment of Jarrod Longcor as Chief ... responsible for structuring, negotiating and executing successful strategic ... as providing management and strategic leadership to the ... leadership team. Mr Longcor brings to ...
    Breaking Medicine Technology:CASI Pharmaceuticals Announces Appointment Of Rajesh C. Shrotriya, MD To The Board Of Directors 2CASI Pharmaceuticals Announces Appointment Of Rajesh C. Shrotriya, MD To The Board Of Directors 3CASI Pharmaceuticals Announces Appointment Of Rajesh C. Shrotriya, MD To The Board Of Directors 4As sales reps see doors close for in-person visits with physicians, digital doors open communication 2As sales reps see doors close for in-person visits with physicians, digital doors open communication 3As sales reps see doors close for in-person visits with physicians, digital doors open communication 4As sales reps see doors close for in-person visits with physicians, digital doors open communication 5Avillion Appoints Jarrod Longcor as Chief Business Officer 2
    ... Mont., May 8, 2012  Bacterin International Holdings, Inc. ... in the development of revolutionary bone graft material ... third national GPO contract, a three-year agreement with ... and contracting company.  The agreement provides Bacterin,s full ...
    ... Heska Corporation (NASDAQ: HSKA ), a provider ... announced that its Board of Directors has declared a cash ... payment will be distributed on July 10, 2012 to stockholders ... to pay a regular quarterly dividend of $0.10 per share ...
    Cached Medicine Technology:Bacterin International Signs Its Third National GPO Contract with Novation 2Bacterin International Signs Its Third National GPO Contract with Novation 3Bacterin International Signs Its Third National GPO Contract with Novation 4Heska Announces Quarterly Dividend of $0.10 Per Share 2
    (Date:9/23/2014)... 2014 Airbus Helicopters Inc. (AHI) is ... as the 2014 Vision Zero Aviation Safety Award ... database, a free flight safety service the company provides ... - Air Medical Specialist for Airbus Helicopters Inc., presented ... check during the Air Medical Transport Conference Annual Community ...
    (Date:9/23/2014)... has been shown to be a driving force ... often develops due to chronic inflammation caused by ... has relatively few effective treatment options. Now, scientists ... demonstrated for the first time in preclinical studies ... as astrocyte elevated gene-1 (AEG-1) halts the development ...
    (Date:9/23/2014)... York, NY (PRWEB) September 23, 2014 ... that it has entered into a contract to provide ... system to Elderplan, Inc., one of New York City’s ... MJHS, will deploy the eCaring system to help enhance ... , “For nearly 30 years, Elderplan has been ...
    (Date:9/23/2014)... EORTC investigators will present the results of their ... 2014 in Madrid. , Joint Symposium: ESMO-ASCO: ... Monday, September 29, 11:00 AM - 12:30 PM, ... Molecular Screening Platforms support new forms of cancer ... program. , Proffered Paper session: Melanoma and ...
    (Date:9/23/2014)... Health has awarded $10.1 million in supplemental funding to ... effects of sex in preclinical and clinical studies. , ... and is a catalyst for considering sex as a ... subjects in preclinical research can obscure key findings related ... progressive approach will result in greater awareness of the ...
    Breaking Medicine News(10 mins):Health News:Protean wins Airbus Helicopters Vision Zero Aviation Safety Award 2Health News:Protean wins Airbus Helicopters Vision Zero Aviation Safety Award 3Health News:Protean wins Airbus Helicopters Vision Zero Aviation Safety Award 4Health News:Study uncovers genetic driver of inflammation, uses it to prevent and treat liver cancer 2Health News:eCaring Signs Care Management Contract with Elderplan, Inc. 2Health News:EORTC presentations at ESMO 2014 Congress 2Health News:EORTC presentations at ESMO 2014 Congress 3Health News:New supplemental awards apply sex and gender lens to NIH-funded research 2Health News:New supplemental awards apply sex and gender lens to NIH-funded research 3
    ... researchers intrigued, egging them on to unlock the secrets embedded ... comprehend the link between profound experiences and their association with ... of the brain of Christian Nuns, while they recalled divine ... MRI of 15 Canadian nuns to get an insight into ...
    ... only reverses the arterial dysfunction caused by fatty foods but ... the meal, according to new research from Indiana University. ... are part of a growing focus on the effect food ... as the postprandial state. After a fatty meal, arteries lose ...
    ... conducted towards pest control have lead to the discovery ... of California, have stated that the newly discovered enzyme ... were initially looking for biological pest controls, might actually ... and other inflammatory diseases. It has been reported that ...
    ... Americans from the year 2000 have been getting poorer. ... in the October issue of the American Journal of Preventive ... climbing rapidly. The researchers have also reported that this growth ... in severe poverty and that ‘moderate’ poverty has grown in ...
    ... transfusions of blood products from recovering patients may help reduce ... of a pandemic in// future. ,The researchers say ... who received blood transfusions from people who had recovered had ... from the flu. ,The study, which is a ...
    ... of the University of Sao Paulo Medical School in Brazil ... getting the best care in case of chronic coronary artery ... to be published in the September edition of the Journal ... to receive their physician-recommended treatment showed a significantly lower incidence ...
    Cached Medicine News:Health News:Researchers seek to demystify brain activity during mystical encounters 2Health News:A Serving of Exercise After That Saturated Fat 2Health News:Pest Control research Leads to Pain Control Discovery 2Health News:Pest Control research Leads to Pain Control Discovery 3Health News:Increasing Levels Of Severe Poverty In US Could Jeopardize Public Health 2Health News:Patient’s Individual Cardiologist Best Judge For Deciding Appropriate Treatment In Chronic Coronary Artery Diseas 2Health News:Patient’s Individual Cardiologist Best Judge For Deciding Appropriate Treatment In Chronic Coronary Artery Diseas 3
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    Medicine Products: